Czirr; Eva

Patent Applications and Registrations

Patent applications and USPTO patent grants for Czirr; Eva.The latest application filed is for "treatment of aging-associated disease with modulators of leukotriene a4 hydrolase".

Company Profile

7.6.10

Czirr; Eva - Foster City CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase Grant 11,426,399 - Campbell , et al. August 30, 2	2022-08-30
Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products Grant 11,413,308 - Braithwaite , et al. August 16, 2	2022-08-16
Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase App 20220226304 - Campbell; Meghan Kerrisk ; et al.	2022-07-21
Treatment of aging-associated disease with modulators of leukotriene A.sub.4 hydrolase Grant 11,344,542 - Campbell , et al. May 31, 2	2022-05-31
Dosing Regimen for Treatment of Cognitive and Motor Impairments with Blood Plasma and Blood Plasma Products App 20210315932 - Braithwaite; Steven P. ; et al.	2021-10-14
Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 Modulators App 20210301013 - Czirr; Eva ; et al.	2021-09-30
Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products Grant 11,040,068 - Braithwaite , et al. June 22, 2	2021-06-22
Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 Modulators App 20210171626 - Czirr; Eva ; et al.	2021-06-10
Dosing Regimen for Treatment of Cognitive and Motor Impairments with Blood Plasma and Blood Plasma Products App 20210060063 - Braithwaite; Steven P. ; et al.	2021-03-04
Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products Grant 10,874,692 - Braithwaite , et al. December 29, 2	2020-12-29
Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase App 20200368220 - Campbell; Meghan Kerrisk ; et al.	2020-11-26
Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase App 20190350917 - Campbell; Meghan Kerrisk ; et al.	2019-11-21
Dosing Regimen for Treatment of Cognitive and Motor Impairments with Blood Plasma and Blood Plasma Products App 20190328782 - Braithwaite; Steven P. ; et al.	2019-10-31
Dosing Regimen for Treatment of Cognitive and Motor Impairments with Blood Plasma and Blood Plasma Products App 20190282617 - Braithwaite; Steven P. ; et al.	2019-09-19
Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products Grant 10,357,513 - Braithwaite , et al. July 23, 2	2019-07-23
Dosing Regimen for Treatment of Cognitive and Motor Impairments with Blood Plasma and Blood Plasma Products App 20180311280 - Braithwaite; Steven P. ; et al.	2018-11-01

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.